Akpinar, I. | Sayin, M. R. | Karabag, T. | Dogan, S. M. | Sen, S. T. | Gudul, N. E. | Aydin, M.

Article | 2013 | HERZ38 ( 3 ) , pp.317 - 320

Superior vena cava anomalies are rare malformations that are typically seen with other congenital cardiac defects. Although a persistent left superior vena cava is the most common anomaly of the systemic venous return in the thorax, its combination with an upper sinus venosus defect and absence of the innominate vein is extremely rare. Here, we report a patient diagnosed with these anomalies based on a bubble study and confirmed with magnetic resonance imaging.

Sayin, M. R. | Dogan, S. M. | Akpinar, I. | Kucuk, E. | Demirtas, A. O. | Yavuz, N.

Editorial | 2014 | HERZ39 ( 5 ) , pp.603 - 604

WOS: 000341095500012 PubMed: 23749197

Sayin, M. R. | Akpinar, I. | Karabag, T. | Aydin, M. | Dogan, S. M.

Editorial | 2013 | HERZ38 ( 4 ) , pp.391 - 392

WOS: 000320243600011 PubMed: 22926541

Akpinar, I. | Salihoglu, Y. S. | Sayin, M. R. | Elri, T. | Karabag, T. | Dogan, S. M. | Aydin, M.

Article | 2013 | HERZ38 ( 1 ) , pp.89 - 92

Takotsubo cardiomyopathy, also known as broken heart syndrome, is similar to acute coronary syndrome. The absence of significant stenosis on coronary angiography and spontaneous improvement of ventricular akinesia are very important features that distinguish this syndrome from acute coronary syndromes. Despite the fact that ST segment elevations are typically encountered, atypical presentation without ECG changes should be kept in mind. We herein report the case of a 61-year-old woman who presented with mid-apical left ventricular akinesia resolving within 24 h.

Sayin, M. R. | Aydin, M. | Dogan, S. M. | Karabag, T. | Cetiner, M. A. | Aktop, Z.

Article | 2013 | HERZ38 ( 3 ) , pp.299 - 305

The aim of this study was to compare the effects of the new generation beta-blocker anti-hypertensive drugs carvedilol and nebivolol on aortic elastic properties which are important indicators of hypertension-related morbidity and mortality. A total of 50 patients who had been diagnosed with stage 1 hypertension according to the Joint National Committee (JNC) VII criteria and who had not received any anti-hypertensive treatment were enrolled in this study. Patients were randomized to receive either 25 mg/day carvedilol (n = 25) or 5 mg/day nebivolol (n = 25) for 3 months at the beginning of the study. Three patients (1 in the carved . . .ilol group, 2 in the nebivolol group) who did not attend 3 month follow-up measurements were excluded from the study. The study was completed with 47 patients (25 women; mean age: 49 +/- 9 years). The aortic elastic parameters such as aortic strain (AS), aortic distensibility (AD), and aortic stiffness index (ASI) were measured by echocardiography. Carvedilol and nebivolol provided a similar decline in both systolic and diastolic blood pressures (-12/-7 mmHg, p < 0.0001 and -12/-7 mmHg, p = 0.002, respectively). Both carvedilol and nebivolol induced a significant decrease in heart rate (-aEuro parts per thousand 15 bpm, p < 0.0001, -aEuro parts per thousand 17 bpm, p < 0.0001, respectively). Even though the heart rate at the end of the treatment was lower for the nebivolol group, the rate of decrease of heart rates between carvedilol and nebivolol groups was not statistically significant (p = 0.074). Both groups demonstrated improvements in the diastolic functions of the left ventricle where certain values showed more improvement for the nebivolol group. Both groups showed improvements in AS and AD rates compared to basal rates; however, these improvements were not statistically significant. Although the improvement rates in AS, AD, and ASI were higher in the nebivolol group compared to the carvedilol group, the differences were not statistically significant (p = 0.091, p = 0.095, p = 0.259, respectively). Both carvedilol and nebivolol induced a decrease in blood pressure and heart rate and showed an improvement in left ventricular diastolic functions. It was observed that both drugs did not cause deterioration in the aortic elastic properties but a slight improvement was seen. However, this improvement was not statistically significant. The improvement was more explicit in the nebivolol group. It may be concluded that nebivolol is slightly superior to carvedilol in reducing heart rate and improving left ventricular diastolic functions. However, further long-term studies with larger sample sizes should be performed in order to better define the effects of both drugs Daha fazlası Daha az